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Purpose: To identify prognostic factors for the outcomes of empirical antifungal 
therapy, we performed a multicenter, prospective, observational study in immuno-
compromised patients with hematological malignancies. Materials and Methods: 
Three hundred seventy-six patients (median age of 48) who had neutropenic fever 
and who received intravenous (IV) itraconazole as an empirical antifungal therapy 
for 3 or more days were analyzed. The patients with possible or probable categories 
of invasive fungal disease (IFD) were enrolled. Results: The overall success rate 
was 51.3% (196/376). Age >50 years, underlying lung disease (co-morbidity), poor 
performance status [Eastern Cooperative Oncology Group (ECOG) ≥2], radiologic 
evidence of IFD, longer duration of baseline neutropenic fever (≥4 days), no antifun-
gal prophylaxis or prophylactic use of antifungal agents other than itraconazole, and 
high tumor burden were associated with decreased success rate in univariate analy-
sis. In multivariate analysis, age >50 years (p=0.009) and poor ECOG performance 
status (p=0.005) were significantly associated with poor outcomes of empirical anti-
fungal therapy. Twenty-two patients (5.9%) discontinued itraconazole therapy due to 
toxicity. Conclusion: We concluded that empirical antifungal therapy with IV itra-
conazole in immunocompromised patients is effective and safe. Additionally, age 
over 50 years and poor performance status were poor prognostic factors for the out-
comes of empirical antifungal therapy with IV itraconazole.
Key Words:   Hematological malignancy, prognosis, itraconazole, empirical anti-
fungal therapy
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evaluate prognostic factors for predicting the outcomes of 
empirical IV itraconazole therapy among clinical data.
MATERIALS AND METHODS
　　　
Study design
This prospective multicenter observational study was per-
formed at 26 medical centers in Korea during the period of 
April 2007 to December 2007. During the period of enroll-
ment, 390 patients with hematological malignancies, such 
as acute leukemia, malignant lymphoma, myelodysplastic 
syndrome (MDS) or multiple myeloma (MM), who had 
neutropenic fever were enrolled. The primary objective of 
this study was to evaluate the overall success rate of empiri-
cal antifungal therapy with IV itraconazole, and the second-
ary objective was to define the poor prognostic factors for 
the outcomes of empirical antifungal therapy with IV itra-
conazole. This protocol was reviewed and approved by the 
ethics committee or institutional review board of each par-
ticipating institution. Written informed consent was obtained 
from all participants before enrollment. This study was con-
ducted according to the Declaration of Helsinki. We used a 
web-based electronic case report form to gather demograph-
ic information and various clinical characteristics of the 
participants. Central monitors conducted both central on-
line data monitoring and on-site monitoring visits to im-
prove data quality.
Patients aged 18 years or older with persistent (more than 
2 days) or recurrent neutropenic fever,14 despite empirical 
broad-spectrum systemic antibacterial therapy, were eligible 
to be enrolled in this study. Fever was defined as a single oral 
temperature above 38.3°C or a temperature above 38.0°C for 
1 hour.10,14 Neutropenia was defined as an absolute neutrophil 
count (ANC) below 0.5×109/L or an ANC below 1.0×109/L 
with a predicted decrease to below 0.5×109/L.10,14 The pa-
tients with possible or probable categories of IFD according 
to the European Organization for Research and Treatment 
of Cancer/Mycoses Study Group (EORTC/MSG) consen-
sus criteria were able to be enrolled in this study.15,16 Patients 
were not eligible if they had a documented (proven) IFD 
according to the EORTC/MSG consensus criteria, except 
Candida infections including candidemia. Other exclusion 
criteria were a history of serious allergy to itraconazole, a 
bilirubin level more than three times the upper limit of nor-
mal (ULN), an aminotransferase or alkaline phosphatase 
level more than five times the ULN, and severe renal dys-
INTRODUCTION
Invasive fungal disease (IFD) is an important cause of mor-
bidity and mortality in patients with hematological malig-
nancies who receive intensive chemotherapy or hematopoi-
etic stem cell transplantation (HSCT), and the incidence of 
IFD has increased over the past decades.1-3 Recently, the inci-
dence of Candida infections has decreased due to the wide-
spread prophylactic use of antifungal agents such as flucon-
azole, whereas Aspergillus infections have become the most 
common cause of IFD.2,3 Delayed diagnosis and treatment 
of invasive Aspergillus infections usually lead to fatal clini-
cal outcomes associated with IFD. However, invasive Asper-
gillus infections are often difficult to diagnose due to nonspe-
cific clinical presentations. Moreover, the identification of 
Aspergillus species from sterile specimens by invasive pro-
cedures may be impractical in patients with unstable clini-
cal situations or with a bleeding tendency. Therefore, empiri-
cal antifungal therapy for suspected IFD was established 
for febrile neutropenic patients with hematological malig-
nancies who present with persistent or recurrent unexplained 
fever despite the use of broad-spectrum antibiotics.4,5 
Although empirical antifungal therapy with deoxycholate 
amphotericin B (D-AMB) has reduced the incidence of 
breakthrough IFD, several serious toxicities related with D-
AMB, including nephrotoxicity, have been frequently re-
ported.6,7 Therefore, liposomal amphotericin B (L-AMB), 
mold active azoles (itraconazole, voriconazole and posacon-
azole) or caspofungin are usually recommended instead of 
D-AMB for empirical antifungal therapy.8-10 Because these 
antifungal agents for empirical antifungal therapy have 
similar efficacy and safety,4,8,9,11 the main concern of empiri-
cal antifungal therapy is no longer choosing the best agent, 
but rather the identification of patients who will be most 
likely to benefit from a given antifungal agent. Several years 
ago, intravenous (IV) itraconazole became available in Ko-
rea, and a relatively low incidence of toxicity has been re-
ported.6,7 
Although there have been many reports on the efficacy 
and safety of IV itraconazole for empirical antifungal thera-
py,6,7,12,13 there have been few reports on the prognostic fac-
tors for predicting the outcomes of empirical antifungal ther-
apy. In this prospective, multicenter, observational study, we 
assessed the success rate of empirical antifungal therapy 
with IV itraconazole in immunocompromised patients with 
hematological malignancies. Additionally, we attempted to 
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cal antifungal therapy as successful if all five of the follow-
ing criteria were met: 1) successful treatment of baseline 
fungal infection, 2) absence of any breakthrough fungal in-
fection during empirical antifungal therapy and within 7 
days after the completion of empirical antifungal therapy, 
3) survival for at least 7 days after discontinuation of em-
pirical antifungal therapy, 4) resolution of fever (defined as 
a temperature below 38°C for at least 2 days) prior to re-
covery from neutropenia, and 5) no premature discontinua-
tion of empirical antifungal therapy due to drug-related tox-
icity or lack of efficacy. 
Baseline fungal infections were defined as those that de-
veloped within the first 48 hours after starting empirical anti-
fungal therapy. Breakthrough fungal infections were defined 
as those that occurred after 3 days of empirical antifungal 
therapy or within 7 days after completion of empirical anti-
fungal therapy. The diagnosis of breakthrough fungal infec-
tion was confirmed when the patients were diagnosed as 
proven or probable IFD according to the EORTC/MSG 
consensus criteria.16 
The safety assessments for empirical antifungal therapy 
with itraconazole were performed and graded according to 
the National Cancer Institute Common Terminology Criteria 
for Adverse Effects, version 3.0.25 Clinical adverse events 
were monitored prospectively during the study period. Tox-
icities of itraconazole, including hepatotoxicity and nephro-
toxicity, were defined when the grade of toxicities reached 
grade 2 or more and an increment of one or more grades 
above the baseline grade level. 
Statistical analysis
The chi-square test was used to compare the success rate of 
empirical antifungal therapy between the high-risk group 
and low-risk group. We also performed the chi-square test 
for evaluating effects of baseline clinical characteristics on 
the outcomes of empirical antifungal therapy with IV itracon-
azole. Stepwise multivariable logistic regression was used to 
identify poor prognostic factors associated with a poor out-
come of empirical antifungal therapy with IV itraconazole. 
We did a second check for collinearity using the Variance 
Inflation Factor (VIF) in multiple linear regression analysis. 
If the VIF values were below 10, we could consider that 
there was no collinearity between independent variables. All 
results were considered statistically significant at p<0.05. 
Two-sided 95% confidence intervals (CI) were calculated 
when appropriate. All calculations were performed with 
SPSS software, version 18.0 (SPSS Inc., Chicago, IL, USA).
function (a calculated creatinine clearance below 30 mL/
min). We also excluded pregnant women and patients who 
were treated with combination therapy with other antifun-
gal agents.
Patients were divided into high- or low-risk groups based 
on underlying tumor burden. High-risk patients included 
those who had newly diagnosed acute myeloid leukemia 
(AML) or acute lymphoblastic leukemia (ALL), MDS with a 
higher score according to the International Prognostic Scor-
ing System (IPSS intermediate-2 or more),17 greater than 
low-intermediate risk of non-Hodgkin’s lymphoma (NHL) 
according to the age-adjusted International Prognostic In-
dex (aaIPI≥2),18 advanced-stage Hodgkin lymphoma (HL) 
according to the Ann Arbor staging system (≥stage 3),19 and 
MM with a high International Staging System score (stage 
3).20 Relapsed or refractory patients were also considered 
high-risk in this study. Among the patients who had under-
gone HSCT, the high-risk group was defined as acute leu-
kemia not in first complete remission (CR), malignant lym-
phoma or MM not in CR, and advanced-stage MDS (IPSS 
intermediate-2 or more).21 
Treatment
IV itraconazole (Janssen Pharmaceutica, Beerse, Belgium) 
treatment was initiated at 200 mg every 12 hours for the 
first 48 hours, and followed by 200 mg once a day from day 
3 to 14. After using IV itraconazole, an itraconazole oral so-
lution (Janssen Pharmaceutica) at a dose of 200-400 mg/
day replaced IV itraconazole when necessary. Participants 
continued treatment with itraconazole until defervescence 
and recovery from neutropenia (ANC over 500 cells/uL for 
at least 3 successive days). Each investigator could deter-
mine the duration of empirical antifungal therapy for the 
patients with baseline or breakthrough fungal infections. 
However, it was recommended that itraconazole treatment 
should be given for at least 14 days or for at least 7 days af-
ter resolution of neutropenia and symptoms. Efficacy and 
safety analyses were conducted for the patients who re-
ceived IV itraconazole for 3 or more days. Patients were ob-
served for up to 7 days after completion of treatment with 
itraconazole for clinical or microbiological evidence of fun-
gal infection.
Analysis of efficacy and safety
The assessments of efficacy for empirical antifungal thera-
py were performed according to the previously reported 
five endpoints.7,22-24 We considered the outcomes of empiri-
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were enrolled during consolidation chemotherapy. Forty-six 
patients (12.2%) receiving HSCT were enrolled and 18 pa-
tients (39.1%) were included in the high-risk group. Twenty-
one patients (5.6%) received an allogeneic HSCT. Among 
284 patients with acute leukemia, 208 (73.2%) patients were 
considered high risk. There were 10 patients (43.5%) with 
MDS included in the high-risk group. Thirty-two patients 
(58.2%) with malignant lymphoma and 7 patients (50.0%) 
with MM were also considered as high risk (Table 1). There 
were 90 patients (23.9%) with co-morbidities. Of those, 
cardiovascular co-morbidity was reported in 42 patients 
(11.2%), diabetes mellitus in 20 (5.3%), liver disease in 19, 
lung disease in 14, renal disease in 4, and other medical 
conditions in 7 patients. At the initiation of empirical anti-
fungal therapy, 123 patients (32.7%) had poor Eastern Co-
operative Oncology Group (ECOG) performance status (2 
or more).
The results of baseline chest X-rays were available in 348 
patients (92.6%). Among them, 70 patients (20.1%) showed 
abnormal findings on chest X-rays. Baseline high-resolu-
tion computerized tomography (CT) scan of the chest was 
performed in 59 patients (15.7%) and 51 patients (86.4%) 
had abnormal findings on CT. Sixteen patients (4.3%) had a 
compatible result for the diagnosis of IFD on the X-rays or 
CT. In 83 patients (22.1%) an enzyme immunoassay for se-
rum galactomannan antigen was performed before initia-
tion of empirical antifungal therapy. Among them, 9 patients 
(10.8%) had a positive result on the serum galactomannan 
test, a cut-off index of 0.5.26,27 The median duration of neu-
tropenia prior to start of empirical antifungal therapy (base-
line neutropenia) was 7 days (range, 1-173). Prolonged base-
line neutropenia (more than 10 days) was observed in 32.4% 
of the patients (n=122). The median duration of neutrope-
nic fever prior to initiation of empirical antifungal therapy 
(baseline neutropenic fever) was 3 days (range, 1-34).
About half of the patients had received an antifungal pro-
phylaxis (n=183, 48.7%). The antifungal agents used for 
prophylaxis were itraconazole (n=69), fluconazole (n=86), 
nystatin (n=21), or D-AMB (n=7). The median duration of 
IV itraconazole for empirical antifungal therapy was 9 days 
(range, 3-28). Seventy-six patients (20%) switched from IV 
to oral itraconazole. Second-line antifungal therapy was con-
ducted in 94 patients (25.0%) after discontinuation of em-
pirical antifungal therapy with IV itraconazole. Antifungal 
agents for second-line therapy included D-AMB (n=84), L-
AMB (n=1), caspofungin (n=7), fluconazole (n=1), or vori-
conazole (n=1). Seventy patients (18.6%) had documented 
RESULTS
 
Clinical characteristics
Among the 390 patients recruited, patients who were stud-
ied for at least 3 days were considered to have completed 
this study whether they continued treatment with IV itra-
conazole or not. The final number of patients evaluated was 
376. The clinical characteristics of the patients treated with 
empirical antifungal therapy with IV itraconazole are pro-
vided in Table 1. The median age was 48 years (range, 18-
80 years). One hundred sixty-five patients were older than 
50 and the male to female ratio was 1.1 : 1. Their underlying 
diseases are reported in Table 1: AML (n=229), ALL (n=55), 
MDS (n=23), NHL (n=52), HL (n=3), and MM (n=14). A 
total of 257 (68.4%) high-risk group of patients were includ-
ed in this study. One hundred-three of 376 patients (27.4%) 
were in relapse or refractory status and 98 patients (26.1%) 
Table 1. Patient Characteristics
Number of 
patients
Percentage 
(%)
Age (median) 48 yrs old
    Age >50 yrs old 165 43.9
Male : Female 195 : 181 51.9 : 48.1
Underlying disease
    AML 229 60.9
        Low-risk/High-risk     53/176
    ALL   55 14.6
        Low-risk/High-risk   23/32
    MDS   23   6.1
        Low-risk/High-risk   13/10
    Malignant lymphoma   55 14.6
        Low-risk/High-risk   23/32
    MM   14   3.7
        Low-risk/High-risk   7/7
ECOG performance status
    0/1 68/185 (253) 67.3
    2/3/4   89/28/6 (123) 32.7
Hematopoietic stem cell  
  transplantation
  46 12.2
    Low-risk/High-risk   28/18
    Autologous HSCT   25   6.6
    Allogeneic HSCT   21   5.6
        Sibling/Unrelated HSCT   10/11
        HLA matched/mismatched 
          HSCT      
15/6
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, 
myelodysplastic syndrome; MM, multiple myeloma; ECOG, Eastern Coop-
erative Oncology Group; HSCT, hematopoietic stem cell transplantation; 
HLA, human leukocyte antigen.
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the underlying hematological malignancies. Previous allo-
geneic HSCT was not significantly associated with a de-
creased success rate (57.1% vs. 51.0%, p=0.657) (Table 3). 
The patients classified into the high-risk group according to 
underlying tumor burden had a significantly lower success 
rate of empirical antifungal therapy than low-risk patients 
(47.5% vs. 59.7%, p=0.035). The patients with relapse or 
refractory acute leukemia had a lower success rate (44.6%, 
33/74) than the patients with acute leukemia in CR (62.0%, 
p=0.036). The patients with co-morbidities were less likely 
to achieve a successful outcome in this study (41.2% vs. 
54.5%, p=0.030) (Table 4). Among them, the patients with 
underlying lung disease showed a significantly lower suc-
cess rate for empirical antifungal therapy (21.4% vs. 52.5%, 
p=0.028). Additionally, the overall success rate of empirical 
antifungal therapy with IV itraconazole was significantly 
decreased in the patients with a poor ECOG performance 
status (≥2) or evidence of IFD on X-rays or CT (p<0.001, p= 
0.009, respectively) (Table 4). There were no significant 
differences in the success rates according to the results of a 
baseline serum galactomannan test. Although the duration 
of baseline neutropenia was not correlated with the success 
rate, the patients with relatively early administration of em-
pirical antifungal therapy (duration of neutropenic fever 
prior to start of empirical antifungal therapy ≤3 days) were 
more likely to achieve a successful outcome in this study 
(55.9% vs. 44.8%, p=0.037). Antifungal prophylaxis prior 
to starting empirical antifungal therapy did not significantly 
affect the success rate of empirical antifungal therapy (Ta-
ble 4). However, the patients who had received an antifun-
gal prophylaxis with itraconazole showed a significantly 
higher success rate than other patients (63.8% vs. 48.5%, 
p=0.024).
In the present study, age over 50 years, underlying lung 
systemic bacterial infections at baseline, and 13 patients 
(3.5%) had baseline fungal infections, including 11 Candi-
da infections and two probable invasive aspergillosis infec-
tions, that were diagnosed within the first 48 hours after en-
try into this study.
Efficacy analysis 
The overall success rate of empirical antifungal therapy with 
IV itraconazole was 51.3% in this study (Table 2). Among 
the 13 patients with baseline fungal infections, 7 patients 
(53.8%) had a successful outcome. Of the 11 baseline Can-
dida infections, 7 patients achieved a successful outcome. 
The rate of occurrence of breakthrough fungal infections 
was 4.3%. Among 16 patients who developed breakthrough 
fungal infections, 8 patients (50.0%) had probable or prov-
en invasive aspergillosis and 5 patients had infections with 
Candida species. The proportion of patients who survived 
for at least 7 days after completion of IV itraconazole thera-
py was 89.9% and the rate of resolution of fever during the 
neutropenic period was 70.2% (Table 2). The median time 
to defervescence after empirical antifungal therapy with IV 
itraconazole was 3 days (range, 1-22). Premature discontin-
uation of itraconazole therapy because of toxicity or lack of 
efficacy occurred in 34.8% (131/376).
Baseline clinical characteristics and success rate of 
empirical antifungal therapy
We analyzed the effects of baseline clinical characteristics 
on the outcomes of empirical antifungal therapy with IV 
itraconazole. The patients over 50 years of age showed a 
lower success rate than the patients aged younger than 50 
years (41.2% vs. 59.2%, p=0.001). The patients with acute 
leukemia had a success rate of 53.2% (151/284) and there 
were no significant differences in success rates according to 
Table 2. Outcomes of Empirical Antifungal Therapy with Itraconazole
Number of patients Percentage (%)
Overall success rate 193/376 51.3
Successful treatment of baseline fungal infection - number of patients/number with infection   7/13 53.8
Absence of breakthrough fungal infection - number of patients/total number 360/376 95.7
Survival for ≥7 days after completion of itraconazole - number of patients/total number 338/376 89.9
Resolution of fever in setting of neutropenia - number of patients/total number 264/376 70.2
Itraconazole discontinued prematurely because of toxicity or lack of efficacy -  
  number of patients/total number
    No 245/376 65.2
    Yes 131/376 34.8
        Lack of efficacy   94/376 25.0
        Drug toxicity   22/376   5.9
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with a poor outcome of empirical antifungal therapy with 
IV itraconazole. 
These two poor prognostic factors (age over 50 years and 
poor ECOG performance status) did not have a major im-
pact on the rates of successful treatment of baseline fungal 
infection and development of breakthrough fungal infec-
tion. However, the patients older than 50 years of age or 
with a poor ECOG performance status (≥2) had a signifi-
cantly lower survival rate for at least 7 days after discontin-
uation of empirical antifungal therapy (p=0.002, p=0.047, 
respectively). The patients older than 50 years of age or 
with a poor ECOG performance status (≥2) also had a sig-
nificantly higher number of premature discontinuation of 
disease (co-morbidity), poor ECOG performance status 
(≥2), evidence of IFD on X-rays or CT, longer duration of 
baseline neutropenic fever (≥4 days), no antifungal prophy-
laxis or prophylactic use of antifungal agents other than 
itraconazole, and high tumor burden (high-risk group) were 
associated with a decreased success rate of empirical anti-
fungal therapy with IV itraconazole in univariate analysis 
(Table 4). There was no collinearity between independent 
variables because all VIF values were below 10. Multivari-
ate analysis using logistic regression revealed that age over 
50 years [p=0.009, hazard ratio (HR)=1.81, 95% CI 1.16-
2.82] and poor ECOG performance status (≥2) (p=0.005, 
HR=1.97, 95% CI 1.23-3.16) were significantly associated 
Table 3. Outcomes of Empirical Antifungal Therapy According to Underlying Disease
 
Overall success rate (%)
p value
Total High-risk group Low-risk group
Total patients 193/376 (51.3) 122/257 (47.5) 71/119 (59.7) 0.035
    Acute leukemia 151/284 (53.2) 104/208 (50.0)   47/76 (61.8) 0.082
        AML 124/229 (54.1)   89/176 (50.6)   35/53 (66.0) 0.059
        ALL     27/55 (49.1)     15/32 (46.9)   12/23 (52.2) 0.787
    Myelodysplastic syndrome       8/23 (34.8)       1/10 (10.0)     7/13 (53.8) 0.074
    Malignant lymphoma     26/55 (47.3)     13/32 (40.6)   13/23 (56.5) 0.283
        NHL     24/52 (46.2)     12/30 (40.0)   12/22 (54.5) 0.400
        HL         2/3 (66.7)         1/2 (50.0)         1/1 (100.0) 1.000
    Multiple myeloma       8/14 (57.1)         4/7 (57.1)       4/7 (57.1) 1.000
HSCT     28/46 (60.9)       9/18 (50.0)   19/28 (67.9) 0.345
    Autologous HSCT     16/25 (64.0)       6/10 (60.0)   10/15 (66.7) 1.000
    Allogeneic HSCT     12/21 (57.1)         3/8 (37.5)     9/13 (69.2) 0.203
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin’s lymphoma; HL, Hodgkin lymphoma; HSCT, hematopoietic stem cell 
transplantation.
Table 4. Outcomes (Overall Success Rate) of Empirical Antifungal Therapy According to the Poor Prognostic Factors 
 Yes (%) No (%) p value
Age >50   68/165 (41.2) 125/211 (59.2) 0.001
Co-morbidities     37/90 (41.1) 156/286 (54.5) 0.030
    Diabetes mellitus       6/20 (30.0) 187/356 (52.5) 0.065
    Lung disease       3/14 (21.4) 190/362 (52.5) 0.028
ECOG performance status ≥2 (vs. 0 or 1)   45/123 (36.6) 148/253 (58.5) <0.001
Galactomannan test-positive         3/9 (33.3)     33/74 (44.6) 0.725
Evidence of IFD on X-rays or CT       3/16 (18.8) 177/336 (52.7) 0.009
Duration of baseline neutropenia
    >6 days (vs. ≤6 days) 101/206 (49.0)   92/170 (54.1) 0.352
    >10 days (vs. ≤10 days)   60/122 (49.2) 133/254 (52.4) 0.583
Duration of baseline neutropenic fever
    ≥4 days (vs. ≤3 days)   69/154 (44.8) 124/222 (55.9) 0.037
    ≥7 days (vs. ≤6 days)     30/72 (41.7) 163/304 (53.6) 0.088
No antifungal prophylaxis   98/193 (50.8)   95/183 (51.9) 0.837
No antifungal prophylaxis or prophylactic use of 
  antifungal agents other than itraconazole 
149/307 (48.5)     44/69 (63.8) 0.024
IFD, invasive fungal disease; ECOG, Eastern Cooperative Oncology Group; CT, computerized tomography.
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trials using IV itraconazole.6,7,12,13 We also identified prog-
nostic factors for predicting the outcomes of empirical anti-
fungal therapy in patients with recurrent or persistent neu-
tropenic fever. Because numerous clinical trials for empirical 
antifungal therapy have demonstrated similar efficacies for 
several antifungal agents,4,6,11,22-24 it might not be necessary 
to further evaluate the differences in efficacy among anti-
fungal agents. Because there are few reports on the prog-
nostic factors for predicting the outcomes of empirical anti-
fungal therapy with IV itraconazole,6,7,12,13 our analysis of 
the effect of potential prognostic factors on the outcomes of 
empirical antifungal therapy might be of value. In this study, 
age over 50 years and poor ECOG performance status (≥2) 
were deemed prognostic factors for predicting a poor out-
come to empirical antifungal therapy with IV itraconazole.
Previously, patients with no antifungal prophylaxis or clin-
ically documented infections showed a better outcome to 
empirical antifungal therapy in a trial with D-AMB.28 How-
ever, we were not able to use those results in clinical practice 
because this early trial did not use the current response cri-
teria for empirical antifungal therapy, and physicians usual-
ly do not consider an empirical D-AMB therapy because of 
toxicity. Although prolonged neutropenia (>10 days) or al-
logeneic HSCT are commonly considered as important 
host factors for developing IFD,15,16 these two factors were 
not significant in our analysis. In our study, a poor outcome 
from empirical administration of IV itraconazole was ob-
empirical antifungal therapy with IV itraconazole due to 
toxicity or lack of efficacy (p=0.017, p=0.001, respective-
ly). Also, the patients over 50 years of age had a significant-
ly lower rate of defervescence during the neutropenic peri-
od than the patients aged younger than 50 years (64.2% vs. 
74.9%, p=0.031) (Table 5). The patients with a poor ECOG 
performance status (≥2) showed a lower trend of deferves-
cence rate during neutropenic period (65.0% vs. 72.7%, 
p=0.149). 
Safety and toxicities
Adverse events were reported in 114 patients (30.3%). 
Among them, hepatotoxicity (n=80, 21.3%), nephrotoxicity 
(n=27, 7.2%), and hypokalemia (n=22, 5.9%) were fre-
quently observed. In 22 patients (5.9%), therapy with itra-
conazole had to be discontinued due to adverse events. The 
reported causes of withdrawal from itraconazole therapy 
due to toxicity were hepatotoxicity (n=17, 77.3%) and neph-
rotoxicity (n=4, 18.2%).
DISCUSSION
This prospective observational study, conducted in the pa-
tients with hematological malignancies at 26 medical cen-
ters, showed that empirical antifungal therapy with IV itra-
conazole was effective and safe compared with previous 
Table 5. Comparison of the Success Rates of Empirical Antifungal Therapy in the Patients Who Presented with Poor Prog-
nostic Factors 
The patients with poor 
ECOG performance 
status (≥2) (n=123) (%)
The patients with age over 
50 yrs (n=165) (%)
High risk group 
(n=257) (%)
Overall success rate   45/123 (36.6)   68/165 (41.2) 122/257 (47.5)
Successful treatment of baseline fungal infection 
- number of patients/number with infection
        4/7 (57.1)         4/9 (44.4)       6/12 (50.0)
Absence of breakthrough fungal infection 
- number of patients/total number
117/123 (95.1) 155/165 (93.9) 245/257 (95.3)
Survival for ≥7 days after completion of itraconazole 
- number of patients/total number
105/123 (85.4) 139/165 (84.2) 224/257 (87.2)
Resolution of fever in setting of neutropenia 
- number of patients/total number
  80/123 (65.0) 106/165 (64.2) 176/257 (68.5)
Itraconazole discontinued prematurely because of 
toxicity or lack of efficacy 
- number of patients/total number
    No   63/123 (51.2)   96/165 (58.2) 150/257 (58.4)
    Yes   60/123 (48.8)   69/165 (41.8) 107/257 (41.6)
        Lack of efficacy   44/123 (35.8)   49/165 (29.7)   77/257 (30.0)
        Drug toxicity   8/123 (6.5)   9/165 (5.5) 17/257 (6.6)
ECOG, Eastern Cooperative Oncology Group.
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is (51.4% in high-risk group, 51.3% in low-risk group). Be-
cause the patients receiving antifungal prophylaxis with 
itraconazole demonstrated better outcomes to empirical an-
tifungal therapy with IV itraconazole, one might consider 
antifungal prophylaxis with itraconazole in high-risk pa-
tients to improve the results of empirical antifungal therapy 
with IV itraconazole. However, we, first, should confirm 
the role of IV itraconazole as an empirical antifungal thera-
py in future studies because there is little information avail-
able on the efficacy and safety of empirical antifungal ther-
apy with IV itraconazole in patients who have received 
antifungal prophylaxis with itraconazole. If data on the blood 
concentration of itraconazole were available, we would have 
been able to explain the exact reason of the greater effec-
tiveness of IV itraconazole in the patients with itraconazole 
prophylaxis, as we would have been able to observe low 
compliance with the itraconazole oral solution. A recent 
study comparing the effectiveness of the mold-active azole 
(voriconazole) versus fluconazole as an antifungal prophy-
laxis in patients undergoing HSCT suggested that intensive 
monitoring for IFD and early administration of appropriate 
empirical antifungal therapy is more important than the anti-
fungal agent chosen for prophylaxis.29 Therefore, intensive 
work-up for identifying IFD and appropriate use of empiri-
cal antifungal therapy are more important in the management 
of patients with persistent neutropenic fever than appropriate 
use of antifungal prophylaxis with mold-active antifungal 
agents. In this study, we did not perform intensive serum ga-
lactomannan tests and radiographic monitoring in all pa-
tients for detecting IFD before initiation of empirical anti-
fungal therapy (galactomannan test in 22.1% and high-
resolution CT scan in 15.7%). We therefore assume that we 
would achieve better outcomes for empirical antifungal 
therapy if we perform a more aggressive work-up during 
neutropenic fever and determine an appropriate time for the 
initiation of empirical antifungal therapy according to the 
concept of preemptive therapy,5 especially in the patients 
with poor prognostic factors. 
Our study has some limitations. Not all study sites select-
ed the same initial antibiotics for neutropenic fever, as the 
trial was done in a more natural setting. We also performed 
this trial in a relatively small number of patients who had a 
prolonged neutropenia (32.4%) or received allogeneic HSCT 
(5.6%). However, the enrolled patients might be good can-
didates for analyzing prognostic factors because a sufficient 
number of patients (68.4%) belonged to the high-risk group 
and they all received the same antifungal agent (IV itracon-
served in specific subgroups of patients: patients older than 
50 years of age; patients with poor ECOG performance sta-
tus (≥2), co-morbidities, especially lung disease, evidence 
of IFD on X-rays or CT, or a longer duration of baseline neu-
tropenic fever (≥4 days); patients who did not receive anti-
fungal prophylaxis with itraconazole (Table 4); and those 
who had a high tumor burden. Among them, age over 50 
years and poor ECOG performance status (≥2) were shown 
to be poor prognostic factors in multivariate analysis. In the 
present study, patients over 50 years of age received empiri-
cal antifungal therapy with IV itraconazole at a median of 3 
days after the onset of neutropenic fever (range, 1-21 days) 
and received a median of 8 days of IV itraconazole (range, 
3-28 days). The patients with poor ECOG performance sta-
tus (≥2) also received the empirical antifungal therapy for a 
sufficient duration (median 7 days). Therefore, we consid-
ered that these patients received an appropriate empirical an-
tifungal therapy. However, they showed significantly lower 
success rates of empirical antifungal therapy because of low 
survival rates for at least 7 days after discontinuation of em-
pirical antifungal therapy and high rates of premature dis-
continuation of empirical antifungal therapy. Therefore, we 
should consider a different strategy, such as a more potent 
or a combination antifungal therapy, in patients with these 
poor prognostic factors. 
Although there were no significant results in multivariate 
analysis, several clinical characteristics were associated with 
a decreased overall success rate of empirical antifungal ther-
apy with IV itraconazole in univariate analysis. Therefore, 
we suggest with caution the use of empirical antifungal ther-
apy with IV itraconazole in patients with underlying lung 
disease (co-morbidity), evidence of IFD on X-rays or CT, 
longer duration of baseline neutropenic fever (≥4 days), no 
antifungal prophylaxis, prophylactic use of antifungal agents 
other than itraconazole, or high tumor burden. Although a 
positive galactomannan test is considered an important in-
dicator of mycological infection,15,16,26 in our study, a posi-
tive baseline galactomannan test was not a significant poor 
prognostic factor. However, as radiological evidence of IFD 
was shown to be a poor prognostic factor in univariate anal-
ysis, we should re-evaluate the role of baseline galactoman-
nan testing in the setting of empirical antifungal therapy, 
because the number of patients who had a result on base-
line galactomannan test was very low (22.1%). 
In this study, the patients with high tumor burden showed 
a decreased success rate of empirical antifungal therapy, de-
spite a similar percentage of previous antifungal prophylax-
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azole) for empirical antifungal therapy. Because therapeutic 
drug monitoring (TDM) for evaluating sufficient blood 
concentrations of itraconazole is important,30 we aim to de-
velop a protocol with regular evaluation of TDM for a fu-
ture trial.
In conclusion, this prospective multicenter observational 
study demonstrated that empirical antifungal therapy with 
IV itraconazole is effective and safe in Korean patients with 
hematological malignancies. Since patients older than 50 
years of age or with poor performance status at the time of 
initiation of empirical antifungal therapy showed poor out-
comes from empirical antifungal therapy, we propose that a 
more aggressive work-up for identifying mycological evi-
dence of IFD, including serum galactomannan test and high-
resolution CT, should be required in these patients. In the fu-
ture, it may be helpful to distinguish which patients would 
benefit most from empirical antifungal therapy and deter-
mine the optimum time of initiation for empirical antifun-
gal therapy during neutropenic fever.
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